Resolution Therapeutics to Showcase Groundbreaking Research at AASLD The Liver Meeting® 2025

Edinburgh, Scotland and London, October 9, 2025 – Resolution Therapeutics Limited, a pioneering clinical-stage biopharmaceutical entity, has announced key presentations at the upcoming American Association for the Study of Liver Disease (AASLD) The Liver Meeting® taking place from November 7-11, 2025, in Washington D.C. This prestigious event stands as a critical platform for disseminating innovative scientific research and medical advancements in liver disease management.

Among the highlights of this meeting, Dr. Paul Brennan, a Clinical Lecturer in Hepatology at the University of Dundee, will present enlightening data from the MATCH 2 clinical trial, showcasing how regenerative macrophage therapy (RMT) has the potential to influence early biomarker changes that correlate with extended survival in patients suffering from advanced cirrhosis. Dr. Brennan's insightful presentation titled "Early modulation of INR and MELD after regenerative macrophage therapy is associated with favorable clinical outcomes at three-year follow-up" will address critical findings regarding how early shifts in liver function markers can predict long-term patient health outcomes.

In addition, Dr. Lara Campana, PhD, co-founder and Senior Vice President of Research and Translational Science at Resolution Therapeutics, will unveil preclinical data illustrating the anti-inflammatory and anti-fibrotic properties of regenerative macrophage therapies in experimental liver fibrosis models. Her poster presentation, titled "Assessment of regenerative macrophage therapy pharmacology supports anti-inflammatory and anti-fibrotic effects in preclinical models of liver fibrosis," is anticipated to generate discussions around the promising applications of macrophage therapy in addressing liver disease.

Members of the Resolution Therapeutics leadership team will be present at the event, allowing for conversations with attendees interested in learning more about the company's transformative work in regenerative medicine. This engagement is crucial in fostering collaborations that may further enhance the field of hepatology and its therapeutic offerings.

About Resolution Therapeutics

Founded as a spinout from the University of Edinburgh, Resolution Therapeutics focuses on developing regenerative macrophage therapy aimed at treating inflammatory and fibrotic diseases. Its flagship product, RTX001, has shown first-in-class potential backed by preclinical evidence demonstrating significant advantages in anti-fibrotic and anti-inflammatory therapy for patients with end-stage liver disease. Resolution is committed to expanding its innovative approach beyond liver disease, exploring applications in various fibrotic and inflammatory indications, including conditions like graft-vs-host disease and lung fibrosis.

With the AASLD meeting set to attract leading experts and professionals from the hepatology field, Resolution Therapeutics is poised to make a significant impact with its advanced research and clinical findings. For further details about their innovations and contributions, visit resolution-tx.com and follow them on LinkedIn for the latest updates.

About AASLD

The American Association for the Study of Liver Disease (AASLD) is a prominent organization dedicated to the prevention and treatment of liver diseases. With a focus on fostering research and education, AASLD is committed to enhancing the scientific and clinical practices within hepatology to advance the care of liver disease patients globally.